Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: Application to BENEFIT and BENEFIT-EXT trials

Transplantation

Volumn 93, Issue 2, 2012, Pages 172-181

  Schnitzler, Mark A ^a   Lentine, Krista L ^a   Axelrod, David ^b   Gheorghian, Adrian ^a   You, Min ^c   Kalsekar, Anupama ^c   L'Italien, Gilbert ^c,d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glomerular filtration rate; Graft failure; Kidney transplantation; Mortality; Regression analysis; Validation

Indexed keywords

BELATACEPT; CYCLOSPORIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; UNITED STATES; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; CHILD; CYCLOSPORINE; DATABASES, FACTUAL; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; UNITED STATES; YOUNG ADULT;

EID: 84855847138     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823ec02a     Document Type: Article

References (33)

1. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451.
2. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450.
5. Weir MR, Wali RK. Minimizing the risk of chronic allograft nephropathy. Transplantation 2009; 87 (8 suppl): S14.
6. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115.
7. Schena FP, Pascoe MD, Alberu J, et al; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
8. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J AmSoc Nephrol 2010; 21: 1587.
9. Larsen CP, Griny ó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528.
10. Kaplan B. Belatacept: The promises and challenges of belatacept and costimulatory blockade. Am J Transplant 2010; 10: 441.
11. Moore J, He X, Shabir S, et al. Development and evaluation of a composite risk score to predict kidney transplant failure. Am J Kidney Dis 2011; 57: 744.
12. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089.
13. Park WD, Griffin MD, Cornell LD, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J AmSoc Nephrol 2010; 21: 1987.
14. Naesens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010; 6: 614.
15. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2011; [epub ahead of print October 12, 2011]. doi: 10.1111/j.1600-6143.2011.03785.x.
16. Medina Pestana J, Grinyo J, Vanrenterghem Y, et al. Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial. Am J Transplant 2011; 11 (suppl 2): 349.
17. Ruppert D, Wand MP, Carroll RJ. Semiparametric regression. Cambridge. Series in Statistical and Probabilistic Mathematics, 2003.
18. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
19. Poggio ED, Batty DS, Flechner SM. Evaluation of renal function in transplantation. Transplantation 2007; 84: 131.
20. He X, Moore J, Shabir S, et al. Comparison of the predictive performance of eGFR formulae for mortality and graft failure in renal transplant recipients. Transplantation 2009; 87: 384.
21. Snyder JJ, Skeans iP, YM, Israni AK, et al. Prediction equations for graft failure based on 12-month eGFR in the US kidney transplant population: A validation study using the international PORT database. Am J Transplant 2010 (Program & Abstracts Issue); (Suppl 10): 332.
22. Wali RK, Weir MR. Chronic allograft dysfunction: Can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant 2008; 13: 614.
23. Fellström B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986.
24. Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant outcome. Am J Transplant 2003; 3: 933.
25. United States Renal Data System. Researcher's Guide to the United States Renal Data System Database, 2010. Available at: http://www.usrds.org/2010/rg/fb/ index.html. Accessed May 7, 2011.
26. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
27. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281.
28. Wolfe RA, McCullough KP, Schaubel DE, Kalbfleisch JD, Murray S, Stegall MD, Leichtman AB. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant 2008; 8(4 Pt 2): 997.
29. Levey AS, Greene T, Kusek JW, et al. A simplified equation to prediction glomerularfiltration ratefromserumcreatinine. JAmSocNephrol2000;11:155A.
30. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100.
31. Schoenberg IJ. Contributions to the problem of approximation of equidistant data by analytic functions. Quart Appl Math 1946; 4: 45.
32. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837.
33. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008; 105: 175.